FDA Oncologic Drug Committee Agrees That “Kitty Fight” With NCI Should Be Negotiated
In Brief: NCI Tells Cooperative Groups To Submit applications For Extra Multimodality Funds
FDA Delays NDA On BCNU, But New Drug Seminar Still Scheduled
Proposed Guidelines For Clinical Tests Of Oncologic Drugs
UCLA, NYU, Ohio States Must Wait Longer For Comprehensive Status
Contact Planned To Encourage Insurers To Reimburse For Cancer Screening
Rosemond Asks Ban On High Tar, Nicotine Cigarettes
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”









